View More Recent Stories

Dec 7, 2015 10:00AM Kite Pharma Presents Phase 1 Results From ZUMA-1 at the 57th American Society of Hematology (ASH) Annual Meeting
Dec 7, 2015 07:04AM Kite Pharma (KITE) Announces KTE-C19 for NHL Granted FDA Breakthrough Therapy Designation
Dec 7, 2015 07:03AM Kite Pharma (KITE) Initiates the ZUMA-4 Study to Support Registration of KTE-C19 for R/R in Children and Young Adults
Dec 7, 2015 06:31AM Kite Pharma (KITE) Receives FDA Breakthrough Status for KTE-C19 in DLBCL, PMBCL, TIFL
Dec 7, 2015 06:31AM Kite Pharma (KITE) Announcs Initiation of KTE-C19 Phase 1/2 in r/r ALL
Dec 7, 2015 06:30AM Kite Pharma Initiates the ZUMA-4 Study to Support Registration of KTE-C19 for Relapsed or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) in Children and Young Adults
Dec 7, 2015 06:30AM Kite Pharma Initiates the ZUMA-4 Study to Support Registration of KTE-C19 for Relapsed or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) in Children and Young Adults
Dec 7, 2015 06:30AM Kite Pharma Receives FDA Breakthrough Therapy Designation for KTE-C19 for the Treatment of Refractory, Aggressive Non Hodgkin Lymphoma (NHL)
Dec 7, 2015 06:30AM Kite Pharma Receives FDA Breakthrough Therapy Designation for KTE-C19 for the Treatment of Refractory, Aggressive Non Hodgkin Lymphoma (NHL)
Dec 3, 2015 08:00AM Kite Pharma and GE Global Research Announce Strategic Collaboration to Automate Manufacturing of Engineered T Cell Therapies
Dec 2, 2015 08:00AM Kite Pharma Initiates the ZUMA-3 Study to Support Registration of KTE-C19 for Relapsed or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL) in Adult Subjects
Nov 12, 2015 04:01PM Kite Pharma Reports Third Quarter 2015 Financial Results and Provides Business Update
Nov 9, 2015 04:01PM Kite Pharma to Host Third Quarter 2015 Financial Results Conference Call and Webcast
Nov 9, 2015 04:01PM Kite Pharma to Host Third Quarter 2015 Financial Results Conference Call and Webcast
Nov 9, 2015 08:00AM Kite Pharma Initiates Phase 2 Clinical Study of KTE-C19 (ZUMA-2) in Patients With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) to Support Registration for a Second Indication
Nov 9, 2015 08:00AM Kite Pharma Initiates Phase 2 Clinical Study of KTE-C19 (ZUMA-2) in Patients With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) to Support Registration for a Second Indication
Nov 5, 2015 09:00AM Kite Pharma to Present Four Abstracts, including Safety and Efficacy Data from the KTE-C19 Phase 1 Study in Patients with Refractory, Aggressive NHL (ZUMA-1), at the 57th American Society of Hematolog
Nov 4, 2015 08:00AM Kite Pharma to Present at Upcoming Investor Conferences in November 2015
Nov 2, 2015 08:00AM Kite Pharma Initiates ZUMA-1 Phase 2 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma (NHL) to Support Registration of KTE-C19
Jun 22, 2015 09:30AM Pre-Open Stock Movers 06/22: (WMB) (CNIT) (FIT) (CI) Higher; (MSO) (ZIOP) (WPZ) Lower (more...)
Jun 20, 2014 10:00AM Kite Pharma, Inc. (NASDAQ: KITE) to Ring The NASDAQ Stock Market Closing Bell
View More Recent Stories